根据提交给美国证券交易委员会(SEC)的文件,Allogene Therapeutics Inc. 在无偿放弃其持有的部分Overland公司股权后,将保留约3%的股份。此举调整了该公司在Overland的持股比例。
根据提交给美国证券交易委员会(SEC)的文件,Allogene Therapeutics Inc. 在无偿放弃其持有的部分Overland公司股权后,将保留约3%的股份。此举调整了该公司在Overland的持股比例。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.